Evidence map›Paper›PMID 31016954›Full record

ReviewSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi2019

[Clinical value of BRAF V600E in thyroid carcinoma and the effect of telomerase reverse transcriptase promoter mutations].

Chunyan Zhao, Zhiyun Jia

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chunyan ZhaoDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, P.R.China.
Zhiyun JiaDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, P.R.China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the incidence of thyroid cancer has been increasing. Researchers around the world have begun to pay more attention to the exploration of its pathogenesis, disease evolution and prognosis. Among them, research in the field of gene molecules has become a hotspot, which includes the mutations of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) and the telomerase reverse transcriptase (TERT) promoter. However, this field is not mature, and there are many problems and challenges need to be solved. This paper explores the value of BRAF mutation in the treatment, recurrence, mortality and prognosis of papillary thyroid carcinoma. In addition, we also explore the relationship between BRAF mutation and TERT promoter mutations and their influences in thyroid cancer. We hope this paper could help later scholars understand the current situation in this field and find a research direction in the future.

Indexed as

MutationPromoter Regions, GeneticAnimalsHumansProto-Oncogene Proteins B-rafTelomeraseThyroid NeoplasmsProto-Oncogene Proteins B-rafTelomerasetelomerase reverse transcriptasethyroid carcinomav-raf murine sarcoma viral oncogene homologue B1

Identifiers

PMID31016954
PMCPMC9929895
OpenAlexW2989333549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.